This week in drug discovery (1-5 July) 

News round-up for 1-5 July by DDW Senior Digital Content Editor Diana Spencer.

The last few days have seen some interesting developments related to gene editing, including the discovery of a new mechanism for genetic programming and evidence in favour of redosing CRISPR-based therapies, as well as significant investment and new indications for gene therapies.

The top stories:

Gene therapy halts progression of rare genetic condition

The findings from a single-patient gene therapy trial in Canada show promise in halting the progression of spastic paraplegia type 50 (SPG50).

Evidence supports redosing with an in vivo CRISPR-based therapy

Intellia Therapeutics has shared the first-ever clinical data demonstrating the potential for redosing with an investigational in vivo CRISPR-based therapy.

Beyond CRISPR: New mechanism for genetic programming discovered

A team of researchers have discovered the bridge recombinase mechanism, a precise and powerful tool to recombine and rearrange DNA in a programmable way.

Gene therapy trial starts in early-onset dementia

AviadoBio has launched its Phase I/II ASPIRE-FTD clinical trial at the Ohio State University in the US.

Beacon Therapeutics raises $170 million in a Series B financing

Life science investors Syncona have committed $42.5 million to Beacon Therapeutics’ $170 million Series B financing round.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free